drugset / Trial / NCT03735849

Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants

NCT03735849

RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics of a human monoclonal antibody (VRC07-523LS) in the sera and mucosae of healthy, HIV-uninfected adults.

Timeline

Start
2019-01-18
Primary completion
2020-12-21
Completion
2020-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject VRC07-523LS Monoclonal antibody 10 mg/kg Intravenous
Subject VRC07-523LS Monoclonal antibody 30 mg/kg Intravenous